Pacira Pharmaceuticals Inc. (PCRX) Drops 8.45% on January 11

Equities Staff |

Pacira Pharmaceuticals Inc. (PCRX) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 8.45% to $61.85, a loss of $-5.7075 per share. Starting at an opening price of $68.18 a share, the stock traded between $61.75 and $68.47 over the course of the trading day. Volume was 895,845 shares over 8,226 trades, against an average daily volume of 975,486 shares and a total float of 36.76 million.

The losses send Pacira Pharmaceuticals Inc. down to a market cap of $2.27 billion. In the last year, Pacira Pharmaceuticals Inc. has traded between $121.95 and $35.78, and its 50-day SMA is currently $64.36 and 200-day SMA is $66.15.

The stock has a P/E Ratio of 241.3.

Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.

Pacira Pharmaceuticals Inc. is based out of Parsippany, NJ and has some 447 employees. Its CEO is David M. Stack.

For a complete fundamental analysis analysis of Pacira Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for PCRX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…